Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection

Fig. 3

CMR-PLGA/OVA NVs-elicited BMDCs maturation in vitro. Flow cytometry (A, C) and statistic (B, D) analysis of antigen presentation in BMDCs following incubation with different groups for 12 h. Flow cytometry (E, G) and statistic (F, H) analysis of matured BMDCs following incubation with different groups for 12 h (n = 3). (I–K) The secretion level of TNF-α, IFN-γ and IL-12 from matured BMDCs treated as described in (A) (n = 3). (I: PBS; II: free OVA; III: PLGA/OVA NVs; IV: R-PLGA/OVA NVs; V: MR-PLGA/OVA NVs; VI: CMR-PLGA/OVA NVs.)

Back to article page